Onconova Therapeutics Inc. logo

ONTX

Onconova Therapeutics Inc. · NASDAQ

This company no longer trades as ONTX. The ticker now belongs to a fund, Corgi ACLS 2x Daily ETF.

Website

Onconova Therapeutics Inc. (ONTX) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for ONTX in the last 30 days. The most recent was published Apr 29, 2024.

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel proprietary multi-kinase inhibitor ON 123300 to target CDK4/6 and other tyrosine kinases. The company's product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressive K-Ras mutated non-small cell lung cancer; and in Phase 1b/2 for recessive dystrophic epidermolysis bullosa. In addition, it is involved in preclinical work investigating rigosertib in COVID-19. The company has a license agreement with SymBio Pharmaceuticals Limited; and license, development, and commercialization agreement with Pint International SA. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.

Latest news

25 items

ONTX FAQ

8 questions
  • What does Onconova Therapeutics Inc. do?
    Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel proprietary multi-kinase inhibitor ON 123300 to target CDK4/6 and other tyrosine kinases. The company's product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressive K-Ras mutated non-small cell lung cancer; and...
  • What is the latest news on ONTX?
    Quantisnow has not tracked any new filings, ratings or press releases for ONTX in the last 30 days. The most recent wire item was published on April 29, 2024.
  • Where does ONTX stock trade?
    Onconova Therapeutics Inc. (ONTX) is listed on NASDAQ.
  • What sector and industry is ONTX in?
    Onconova Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • When did Onconova Therapeutics Inc. go public?
    Onconova Therapeutics Inc. (ONTX) completed its IPO in 2013.
  • What are analysts saying about ONTX?
    Onconova Therapeutics Inc. has had 1 recent analyst action on file. The most recent action was from Ladenburg Thalmann: Buy with a $7.00 price target on 2022-03-01. Recent price targets cluster around $7.00.
  • What companies are similar to ONTX?
    Notable peers in the same industry include ABT (Abbott Laboratories), JNJ (Johnson & Johnson), MRK (Merck & Company Inc.), NVO (Novo Nordisk A/S), AZN (AstraZeneca PLC). Compare ONTX side-by-side with any of them on Quantisnow.
  • How can I track ONTX on Quantisnow?
    Quantisnow aggregates Onconova Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ONTX to receive live email and push alerts on every new disclosure.